{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T18:35:00Z","timestamp":1770748500505,"version":"3.50.0"},"reference-count":19,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2025,3,1]]},"abstract":"Importance<\/jats:title>Psoriasis is a chronic, immune-mediated skin disease with an unmet need for biologic treatment options.<\/jats:p><\/jats:sec>Objective<\/jats:title>To assess the safety, pharmacokinetics, and efficacy of QX004N in healthy individuals and patients with moderate to severe plaque psoriasis in China.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This randomized clinical trial was composed of 2 parts. Part 1 was a first-in-human, single-ascending-dose, phase 1a clinical trial conducted from November 2, 2021, to January 16, 2023. Part 2 was a double-blind, multiple dose-escalation, phase 1b clinical trial conducted from February 15, 2023, to January 5, 2024, at 5 clinical centers in China, involving patients with moderate to severe plaque psoriasis.<\/jats:p><\/jats:sec>Interventions<\/jats:title>In part 1, healthy participants in each cohort were assigned in a 4:1 ratio to receive a single subcutaneous injection of QX004N (ranging from 10 mg to 600 mg) or placebo. In part 2, patients in each cohort were assigned in a 4:1 ratio to receive QX004N or placebo at doses of 150 mg, 300 mg, and 600 mg once every 2 weeks.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>For part 1, the primary outcome was the safety of a single dose of QX004N in healthy participants, and the secondary outcome was the pharmacokinetic profile. For part 2, the primary efficacy end point was the proportion of patients achieving at least 75% improvement in Psoriasis Area and Severity Index (PASI 75) by week 12; other efficacy end points were considered secondary.<\/jats:p><\/jats:sec>Results<\/jats:title>The phase 1a clinical trial (part 1) enrolled 55 healthy participants (mean [SD] age, 35.9 [6.0] years; 30 [54.5%] female), and the phase 1b clinical trial (part 2) enrolled 30 patients with moderate to severe plaque psoriasis. The mean (SD) age of QX004N-treated participants in part 2 was 41.4 (7.5) years, and 19 of 24 QX004N-treated participants (79.2%) were male. The mean (SD) age of the placebo cohort in part 2 was 35.3 (8.4) years, and 5 of 6 placebo-treated participants (83.3%) were male. QX004N exhibited linear pharmacokinetics and was tolerated well in both healthy participants and patients with psoriasis. Most adverse events were mild to moderate in severity, with no drug-related serious adverse events reported. The proportion of patients receiving QX004N who achieved PASI 75 at week 12 and PASI 90 (90% improvement in PASI) at week 16 in the 150-mg, 300-mg, and 600-mg cohorts was 100%, significantly higher than that in the placebo cohorts (33.3%). The maximum proportion of patients achieving Investigator\u2019s Global Assessment score of 0 or 1 was 100% in the 3 QX004N cohorts.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this randomized clinical trial, QX004N was well tolerated and demonstrated superior efficacy compared to placebo in patients with moderate to severe plaque psoriasis.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>Chinese Clinical Trial Registry Identifier: CTR20212313 and CTR20223457<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamadermatol.2024.5059","type":"journal-article","created":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T20:31:57Z","timestamp":1733949117000},"page":"247","source":"Crossref","is-referenced-by-count":3,"title":["Safety and Efficacy of Anti\u2013IL-23 Monoclonal Antibody QX004N for Patients With Psoriasis"],"prefix":"10.1001","volume":"161","author":[{"given":"Xiaojiao","family":"Li","sequence":"first","affiliation":[{"name":"Phase I Clinical Trial Center, the First Hospital of Jilin University, Changchun, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Li","sequence":"additional","affiliation":[{"name":"Phase I Clinical Trial Center, the First Hospital of Jilin University, Changchun, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deming","family":"Yang","sequence":"additional","affiliation":[{"name":"Phase I Clinical Trial Center, the First Hospital of Jilin University, Changchun, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Wang","sequence":"additional","affiliation":[{"name":"Phase I Clinical Trial Center, the First Hospital of Jilin University, Changchun, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qianqian","family":"Li","sequence":"additional","affiliation":[{"name":"Phase I Clinical Trial Center, the First Hospital of Jilin University, Changchun, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, the First Hospital of Jilin University, Changchun, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Fang","sequence":"additional","affiliation":[{"name":"Qyuns Therapeutics Co, Ltd, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingrui","family":"Liu","sequence":"additional","affiliation":[{"name":"Phase I Clinical Trial Center, the First Hospital of Jilin University, Changchun, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Phase I Clinical Trial Center, the First Hospital of Jilin University, Changchun, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Wu","sequence":"additional","affiliation":[{"name":"Phase I Clinical Trial Center, the First Hospital of Jilin University, Changchun, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cuiyun","family":"Li","sequence":"additional","affiliation":[{"name":"Phase I Clinical Trial Center, the First Hospital of Jilin University, Changchun, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxue","family":"Zhu","sequence":"additional","affiliation":[{"name":"Phase I Clinical Trial Center, the First Hospital of Jilin University, Changchun, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanhua","family":"Ding","sequence":"additional","affiliation":[{"name":"Phase I Clinical Trial Center, the First Hospital of Jilin University, Changchun, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanshan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, the First Hospital of Jilin University, Changchun, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"1","key":"doi240059r1","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s40259-022-00569-z","article-title":"Biologic and small-molecule therapies for moderate-to-severe psoriasis: focus on psoriasis comorbidities.","volume":"37","author":"Jiang","year":"2023","journal-title":"BioDrugs"},{"issue":"12","key":"doi240059r2","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1080\/14712598.2022.2132143","article-title":"Anti-IL 23 biologics for the treatment of plaque psoriasis.","volume":"22","author":"Vu","year":"2022","journal-title":"Expert Opin Biol Ther"},{"issue":"10281","key":"doi240059r3","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis.","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"doi240059r4","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.982238","article-title":"The regulatory mechanism and potential application of IL-23 in autoimmune diseases.","volume":"13","author":"Xiong","year":"2022","journal-title":"Front Pharmacol"},{"issue":"2","key":"doi240059r5","doi-asserted-by":"publisher","first-page":"318","DOI":"10.3390\/biomedicines11020318","article-title":"The impact of treatment with IL-17\/IL-23 inhibitors on subclinical atherosclerosis in patients with plaque psoriasis and\/or psoriatic arthritis: a systematic review.","volume":"11","author":"Tsiogka","year":"2023","journal-title":"Biomedicines"},{"key":"doi240059r6","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2147\/CCID.S296544","article-title":"Risankizumab for the treatment of moderate to severe psoriasis: impact on health-related quality of life and psychological wellbeing.","volume":"16","author":"Gracia-Caza\u00f1a","year":"2023","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"3","key":"doi240059r7","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s12026-022-09356-y","article-title":"Anti-IL23 biologic therapies in the treatment of psoriasis: real-world experience versus clinical trials data.","volume":"71","author":"Ruggiero","year":"2023","journal-title":"Immunol Res"},{"issue":"10275","key":"doi240059r8","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/S0140-6736(21)00184-7","article-title":"Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis.","volume":"397","author":"Ghoreschi","year":"2021","journal-title":"Lancet"},{"issue":"3","key":"doi240059r9","doi-asserted-by":"publisher","first-page":"134","DOI":"10.12788\/j.sder.2018.039","article-title":"TNF inhibitors for psoriasis.","volume":"37","author":"Chima","year":"2018","journal-title":"Semin Cutan Med Surg"},{"key":"doi240059r10","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.2147\/CCID.S387759","article-title":"Drug survival outcomes associated with the real-world use of ixekizumab, secukinumab, guselkumab, and adalimumab for the treatment of plaque psoriasis in China: a 52-week single-center retrospective study.","volume":"15","author":"Li","year":"2022","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"5","key":"doi240059r11","doi-asserted-by":"publisher","first-page":"953","DOI":"10.5114\/ada.2022.120886","article-title":"Efficacy of guselkumab compared with adalimumab for psoriasis: a meta-analysis of randomized controlled studies.","volume":"39","author":"Fu","year":"2022","journal-title":"Postepy Dermatol Alergol"},{"key":"doi240059r12","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.2147\/CCID.S364640","article-title":"Guselkumab, risankizumab, and tildrakizumab in the management of psoriasis: a review of the real-world evidence.","volume":"15","author":"Ruggiero","year":"2022","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"6","key":"doi240059r13","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1080\/09546634.2022.2081655","article-title":"Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study.","volume":"33","author":"Megna","year":"2022","journal-title":"J Dermatolog Treat"},{"issue":"12","key":"doi240059r14","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1002\/jcph.1473","article-title":"Pharmacokinetics of risankizumab in Asian healthy subjects and patients with moderate to severe plaque psoriasis, generalized pustular psoriasis, and erythrodermic psoriasis.","volume":"59","author":"Khatri","year":"2019","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"doi240059r17","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial.","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"doi240059r18","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.","volume":"76","author":"Reich","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"10148","key":"doi240059r19","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"key":"doi240059r15","unstructured":"US Food and Drug Admistration. SKYRIZI\u2013risankizumab-rzaa injection. Accessed May 21, 2024. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=7148c8eb-b39e-e20a-6494-a6df82392858"},{"key":"doi240059r16","unstructured":"US Food and Drug Admistration. TREMFYA\u2013guselkumab injection. Accessed May 24, 2024. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=1e6dc9ae-1c4c-42d9-87aa-c315ecc51b56"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2827347\/jamadermatology_li_2024_oi_240059_1741115885.56494.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T16:05:18Z","timestamp":1742400318000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2827347"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2025,3,1]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2024.5059","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,1]]}}}